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Abstract
Background
The 13-valent pneumococcal vaccine (PCV13) was introduced in Cambodia in January
2015. There are limited data concerning the common serotypes causing invasive pneumo-
coccal disease (IPD). Knowledge of the circulating pneumococcal serotypes is important to
monitor epidemiological changes before and after vaccine implementation.
Methods
All episodes of IPD defined by the isolation of Streptococcus pneumoniae from blood, cere-
brospinal fluid or other sterile site in Cambodian children admitted to the Angkor Hospital for
Children in Siem Reap, Northwestern Cambodia, between 1st January 2007 and 1st July
2012 were retrospectively studied. Streptococcus pneumoniae isolates that could be
retrieved underwent phenotypic typing and whole genome sequencing.
Results
There were 90 Cambodian children hospitalized with IPD with a median (IQR) age of 2.3
years (0.9–6.2). The case fatality was 15.6% (95% CI 8–23). Of 50 Streptococcus pneumo-
niae isolates available for further testing, 46% were penicillin non-susceptible and 8% were
ceftriaxone non-susceptible, 78% were cotrimoxazole resistant, 30% were erythromycin
resistant and 30% chloramphenicol resistant. There were no significant changes in resis-
tance levels over the five-year period. The most common serotypes were 1 (11/50; 22%),
23F (8/50; 16%), 14 (6/50; 12%), 5 (5/50; 10%) and 19A (3/50; 6%). Coverage by PCV7,
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PCV10 and PCV13 was 44%, 76% and 92% respectively. We identified novel multilocus
sequence types and resistotypes using whole genome sequencing.
Conclusions
This study suggests IPD is an important disease in Cambodian children and can have a sig-
nificant mortality. PCV13 coverage of the serotypes determined in studied strains was high
and consistent with another recent study. The phenotypic resistance patterns observed
were similar to other regional studies. The use of whole genome sequencing in the present
study provides additional typing and resistance information together with the description of
novel sequence types and resistotypes.
Introduction
Streptococcus pneumoniae (pneumococcus, S. pneumoniae) causes an estimated one million
childhood deaths each year, mostly in developing countries [1]. S. pneumoniae is carried in the
upper airways of healthy individuals, particularly infants and children and is easily transmitted
between household members [2]. Strains carried in the upper airways are considered the reser-
voir of isolates that may cause lower respiratory tract infections, pneumonia and invasive dis-
ease. The polysaccharide capsule is an important virulence factor of the pneumococcus and the
distribution of the>90 different capsular serotypes varies geographically and over time [3].
The serotypes causing disease in Asia have been recently reviewed but data is limited for Cam-
bodia [3–6]. In a recent study of S. pneumoniae, 88% of 43 invasive isolates serotypes causing
invasive pediatric disease in Cambodia in 2013–14 had a serotype covered by the PCV13 vac-
cine [7].
Studies conducted by the Global Alliance for Vaccines and Immunization (GAVI Alliance)
and the Pneumonia Etiology Research Child Health Project (PERCH) are contributing to our
understanding of childhood pneumonia and associated diseases in Asia but have not so far
included Cambodia [8]. Pneumococcal conjugate vaccines (PCV) active against 7, 10 or 13 of
the most common disease-causing serotypes of S. pneumoniae are now being deployed in these
areas [9]. Data from countries surrounding Cambodia such as Laos, Thailand and Vietnam
show that the PCV7 has coverage of 39–53%, PCV10 coverage of 34–78% and PCV13 coverage
of 45–81% of cases [3, 8, 10–15]. Knowledge of pneumococcal serotypes from invasive disease
in the pediatric population of Cambodia will support the Cambodian public health authorities
make informed decisions about vaccination implementation. Monitoring of the prevailing
serotypes will also be important to observe potential serotype replacement.
In Cambodia, and other developing countries, where access to healthcare is limited and
unregulated drug prescribing is commonplace, antimicrobial resistance is increasing [5, 16]. It
is important to define the extent of resistance to the antimicrobials in common use in each
country against important pathogens to inform antimicrobial guidelines both locally and coun-
trywide. The high level of antimicrobial resistance in these countries is worrying and supports
the argument for pneumococcal vaccination.
We report on invasive pneumococcal disease in children attending a children’s hospital in
Siem Reap, Northwestern Cambodia between 2007 and 2012, and describe the antibiotic resis-
tance profiles, serotypes, vaccine coverage and multilocus sequence types on a subset of iso-
lates. This study complements and extends the data from the 2013–4 surveillance study [7].
Invasive Pneumococcal Infections in Cambodian Children
PLOS ONE | DOI:10.1371/journal.pone.0159358 July 22, 2016 2 / 12
Materials and Methods
Hospital setting
During the study period, Angkor Hospital for Children (AHC) was a 50-bedded charitably
funded pediatric hospital in Siem Reap, Northwestern Cambodia. The hospital provides free
medical care for children<16 years of age, with approximately 125,000 attendances and 4,000
admissions each year over the study period, however the hospital has since grown to>80 beds,
the current available treatments are described in more detail online (http://angkorhospital.org/
treatment/). S. pneumoniae causes approximately 10% of bloodstream infections in this hospi-
tal [17].
Patients studied
Children admitted to AHC who had S. pneumoniae cultured from a sterile site (blood, cerebro-
spinal fluid (CSF), joint fluid or other sterile site), between 1st January 2007 and 1st July 2012
were defined as having invasive pneumococcal disease (IPD). Cases were identified from the
Microbiology Department laboratory records. Demographic and clinical data were retrieved
from the hospital electronic database.
Microbiology methods
Sterile body fluids were processed using standard microbiological methods. S. pneumoniae iso-
lates were identified by colony morphology, lack of catalase reaction, Gram stain, susceptibility
to optochin and bile solubility. Antimicrobial susceptibility was determined for all available
strains by disk diffusion to oxacillin, co-trimoxazole, ceftriaxone, erythromycin and chloram-
phenicol, and by E-test (Biomerieux, France) to penicillin, co-trimoxazole and ceftriaxone in
accordance with CLSI guidelines [18]. Isolates were stored at -80°C in Tryptone Soya Broth
(TSB) with 10% glycerol and transported to Oxford for further testing where serotyping was
performed using the Quellung reaction.
Whole genome sequencing
Whole Genome Sequencing (WGS) was performed to confirm the capsule serotype, determine
multilocus sequence type (MLST) (http://spneumoniae.mlst.net) and resistotype in silico.
Reads were mapped to the serotype 6B resistant S. pneumoniae reference genome (RefSeq:
NC_014498) isolated in Spain using a validated in-house bioinformatics pipeline [19]. The de
novo reads were assembled using Velvet to determine the different capsule types [20]. EBURST
version 3 was used to determine the relationships with regards to MLST types [21]. The resis-
tance genes previously described (folA, folP, pbp1A, pbp2B, pbp2X) were identified using a
nucmer search for the flanking region using the aligned and assembled DNA as previously
described [22–25]. Where the gene could not be identified from the aligned DNA the de novo
gene assembly was interrogated for the resistance gene. Each gene was aligned and translated
in Geneious v8.1.6 (Biomatters Ltd, US) and the resistance markers were documented.
Data analysis
The data were analysed using STATA v13.1 (StataCorp, Texas, USA).
Ethical permission
The Institutional Review Board at AHC and the Oxford Tropical Research Ethics Committee
(506–12) gave ethical approval for this retrospective study. As the study was retrospective in
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nature, spanning a five-year period, consent was not obtained from each patient when the
study was conceived in 2012. All patient information was anonymised and de-identified during
the laboratory work. The final analysis was performed on data that was non-identifiable.
Results
Patient characteristics
There were 90 confirmed IPD patient episodes during the study period (78 isolates from blood,
4 CSF, 8 other sterile fluids). The median (IQR, range) age of the children was 2.3 years (0.9–
6.2; 1 day-14.5 years) with 37 (41.1%) under two years of age, 25 (27.8%) two to four years of
age and 28 (31.1%) over five years. Forty (44.4%) patients were female. The final clinical diag-
nosis given by the responsible clinician was severe pneumonia in 47 (52.2%) patients, bacter-
emia in 16 (17.8%), septic shock in 12 (13.3%), meningitis in eight (8.9%), cellulitis in two
(2.2%), pyomyositis in one (1.1%), unrelated infections in two (1.1% each, one urinary tract
infection and one dengue infection) and no diagnosis recorded in two (2.2%). Thirteen chil-
dren died in hospital and one was discharged moribund to die at home, giving a case fatality
rate of 15.6% (95% CI 8–23). Ten of the 62 (16.0%) children<5-years old died (95% CI 6.7–
25.5).
Quellung serotypes
There were 50 strains that were viable when sub-cultured and available for further testing.
Among the 50 strains there were 16 different serotypes (S1 Table together with year of isola-
tion). The five most frequent serotypes for all ages were serotypes 1 (n = 11 strains, 22%), 23F
(n = 8, 16%), 14 (n = 6, 12%), 5 (n = 5, 10%), 19A (n = 3, 6%) 6A (n = 3, 6%) and 6B (n = 3,
6%) (Fig 1). The PCV7 vaccine (4, 6B, 9V, 14, 18C, 19F and 23F) would cover 22 of the cases
(44%; 95% CI 30–58); PCV10 (PCV7 with additional serotypes 1, 5 and 7F) would cover 38
cases (76%, 95% CI 64–88); and PCV13 (PCV10 plus 3, 6A and 19A) would cover 46 cases
(92%; 95% CI 84–100), including 21 infections in children under two (91%; 95% CI 78–100).
Overall, four (8.0%) strains were not covered by the current vaccines.
MLST sequence types
We determined 23 different sequence types (STs) with seven (13.5%) new STs (two for serotype
23F and one each for 18C, 23A, 6B, 19F and 3) (Table 1). The most numerous STs were ST217
(n = 11) that were all serotype 1, ST289 (n = 5) all serotype 5, ST782 (n = 5) all serotype 14,
ST9050 (n = 4) all serotype 23F and ST320 (n = 3) all serotype 19A.
Antibiotic resistance and resistotyping
The MIC50, MIC90 (range, interquartile range) for penicillin MIC in 50 isolates was 0.06μg/ml,
0.50μg/ml (0.03–2.0μg/ml, 0.12–0.25μg/ml). All isolates were penicillin susceptible using the
recently revised CLSI pneumonia breakpoints (susceptible2 μg/ml) [18]. By the meningitis
breakpoints, which are often applied in epidemiological analyses and where penicillin non-sus-
ceptibility is indicated by an MIC of>0.06μg/ml [18], 46% of strains were non-susceptible to
penicillin and in three strains the penicillin MIC was1mg/ml (Table 2). Forty-six (92%) iso-
lates were susceptible to ceftriaxone by meningitis breakpoints with four intermediate strains
(MICs of 0.5 μg/ml (n = 2), and 1.0μg/ml (n = 2)), which were also non-susceptible to penicillin
(MICs of 0.5 μg/ml, 1.0μg/ml (n = 2) and 1.5μg/ml). One strain was serotype 19F (MICs
0.5 μg/ml), one 23F (MICs of 1.0 μg/ml), and two 19A (MLST ST320), which are covered by
PCV13. When categorized by clinical syndrome, one strain causing meningitis was penicillin
Invasive Pneumococcal Infections in Cambodian Children
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non-susceptible (MIC 0.096 μg/ml) using the CLSI meningitis breakpoints but no strains were
ceftriaxone non-susceptible (Tables 2 and 3) [18]. Resistance to cotrimoxazole was found in
78% of strains and to erythromycin and chloramphenicol independently in 30% of strains.
There were 39 (78%) strains resistant to at least one antimicrobial and 23 (46.0%) displayed
resistance to three or more drugs, including known resistant serotypes 23F (n = 6; STs 81, 242,
9050 and a new ST), 14 (n = 5; STs 63 and 782) and 19A (n = 3; ST 320).
Genotyping for known functional polymorphisms causing penicillin and co-trimoxazole
resistance are in Table 1. Ten different penicillin determinants were observed with the most
common (genotype: NSQFLAGSFSYLTYTMAAGVIPTAV) found in 46.2% of isolates, for
which all of the penicillin and ceftriaxone MICs were<0.096 μg/ml. The second most common
genotype (at 14%) included the two ceftriaxone intermediate strains and all strains were resis-
tant to penicillin (genotype: GTGYMVGSFSYLTYATSSSYLTSVI). We also analyzed the folA
(dihydrofolate reductase [DHFR]) and folP (dihydropteroate synthase [DHPS]) sequences of
the isolates. In the DHFR enzyme all the resistant isolates had a substitution of leucine for iso-
leucine at position 100. Eight co-trimoxazole resistance variants were observed in folP with a
6bp insertion leading to the insertion of two additional amino acids in DHPS the most com-
mon [23]. Three of the co-trimoxazole variants in the current study have not previously been
reported. Two DHFS patterns were observed for the strains susceptible to co-trimoxazole, they
mainly differed at one base from those resistant (amino acid 111; alanine in the sensitive strains
and proline in the resistant strains).
Fig 1. Serotype results by age and vaccine coverage.
doi:10.1371/journal.pone.0159358.g001
Invasive Pneumococcal Infections in Cambodian Children
PLOS ONE | DOI:10.1371/journal.pone.0159358 July 22, 2016 5 / 12
T
ab
le
1.
M
L
S
T
,s
er
o
ty
p
in
g
an
d
re
si
st
o
ty
p
in
g
d
at
a
fo
r
in
va
si
ve
S
.p
ne
um
on
ia
e
is
o
la
te
s.
S
er
o
ty
p
e
M
L
S
T
C
C
M
L
S
T
S
T
N
u
m
b
er
,
n
=
50
(%
)
D
H
F
S
va
ri
an
t#
D
H
P
S
*
va
ri
an
t
C
o
-t
ri
m
o
xa
zo
le
M
IC
re
su
lt
F
u
n
ct
io
n
al
p
en
ic
ill
in
si
n
g
le
n
u
cl
eo
ti
d
e
p
o
ly
m
o
rp
h
is
m
s
(S
N
P
s;
p
b
p
1A
|p
b
p
2B
|
p
b
p
2X
)
P
en
ic
ill
in
M
IC
re
su
lt
S
u
sc
ep
ti
b
le
R
es
is
ta
n
t
S
u
sc
ep
ti
b
le
N
o
n
-
su
sc
ep
ti
b
le
1
21
7
21
7
11
(1
00
)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
11
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
M
A
A
G
V
IP
T
A
V
10
1
14
63
78
2
5
(8
3.
3)
E
D
H
M
K
P
IA
Y
V
A
D
L
K
P
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
2
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
A
T
A
A
G
V
IP
T
A
V
0
2
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
3
N
S
Q
F
LA
G
M
P
S
Y
LT
Y
A
T
A
A
G
V
IP
T
A
V
0
3
63
63
1
(1
6.
7)
E
D
Y
M
K
S
IT
Y
V
A
D
L
K
P
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
0
1
23
F
90
50
90
50
4
(5
0)
E
D
Y
M
K
S
IV
H
IG
D
L
K
S
H
S
T
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
S
F
P
S
Q
R
F
G
T
T
A
A
G
V
IP
T
A
V
0
1
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
3
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
1
2
81
81
1
(1
2.
5)
D
D
H
M
K
S
LA
H
V
A
D
L
K
P
H
S
T
S
T
R
P
G
S
S
S
Y
V
E
IE
0
1
G
T
G
Y
M
V
G
S
F
-Y
LT
Y
A
T
S
S
S
Y
LT
S
V
I¶
0
1
24
2
1
(1
2.
5)
E
D
H
M
K
S
LA
H
V
A
E
L
K
P
Q
Y
K
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
A
T
S
S
S
Y
LT
S
V
I
1
0
ne
w
S
T
1
1
(1
2.
5)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
1
0
ne
w
S
T
2
1
(1
2.
5)
E
E
H
M
K
P
IA
Q
V
A
E
L
K
P
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
G
T
G
Y
M
V
G
P
M
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
1
0
5
28
9
28
9
5
(1
00
)
E
E
H
M
K
P
IA
Q
V
A
E
IK
A
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
4
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
4
0
S
T
R
P
G
S
S
Y
V
E
IE
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
1
0
19
A
32
0
32
0
3
(1
00
)
E
D
Y
M
K
S
IT
Y
V
A
D
L
K
P
Q
F
T
S
T
R
P
G
S
S
Y
S
Y
V
E
IE
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
A
T
S
S
S
Y
LT
S
V
I
0
1
S
T
R
P
G
S
S
Y
V
E
IE
IE
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
A
T
S
S
S
Y
LT
S
V
I
0
1
S
T
R
P
G
S
S
Y
V
E
IE
IE
0
1
IT
G
Y
M
V
G
S
F
S
Y
LT
Y
A
T
S
S
S
Y
LT
S
V
M
0
1
6B
15
6
95
2
(6
6)
E
D
H
M
K
LI
A
H
V
V
E
L
K
S
H
F
A
S
T
R
P
G
R
S
S
Y
V
E
IE
0
2
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
A
T
S
S
S
Y
LT
S
V
I
0
2
15
6
ne
w
S
T
1
(3
3)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
R
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
1
0
9V
15
6
28
0
1
(1
00
)
E
E
H
M
K
P
IA
Q
V
D
E
IK
P
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
1
0
24
F
15
6
55
49
1
(1
00
)
E
E
H
M
K
P
IA
Q
V
A
E
IK
A
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
A
T
A
A
G
V
IP
T
A
V
1
0
6A
S
in
gl
et
on
54
21
2
(6
7)
E
D
H
M
K
S
LA
H
V
A
E
L
K
P
Q
Y
S
S
T
R
P
G
S
S
Y
G
Y
V
E
IE
§
0
2
N
T
G
Y
M
V
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
0
2
in
co
m
pl
et
e$
1
(3
3)
E
D
H
IK
P
IT
Y
V
D
D
L
K
P
H
F
A
S
T
R
P
G
S
S
Y
S
Y
V
E
IE
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
0
1
18
C
35
94
35
94
1
(5
0)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
1
0
ne
w
S
T
1
(5
0)
E
D
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
R
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
M
A
A
G
V
IP
T
A
V
1
0
3
49
09
49
09
1
(5
0)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
M
A
A
G
V
IP
T
A
V
0
1
n
ew
S
T
1
(5
0)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
1
0
19
F
S
in
gl
et
on
ne
w
S
T
1
(5
0)
E
D
H
M
K
LI
A
H
V
V
E
L
K
S
H
F
A
S
T
R
P
G
S
S
Y
Y
V
E
IE
§
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
0
1
In
co
m
pl
et
e$
1
(5
0)
D
D
H
M
K
S
LA
H
V
A
D
L
K
P
H
S
T
S
T
R
P
G
S
S
Y
Y
V
E
IE
§
0
1
G
T
G
Y
M
V
G
S
F
S
Y
LT
Y
T
T
A
A
G
V
IP
T
A
V
0
1
38
31
0
1
(1
00
)
E
E
H
M
K
P
IA
Q
V
A
E
IK
P
H
F
A
S
T
R
P
G
S
S
Y
V
E
IE
1
0
N
S
Q
F
L
A
G
S
F
S
Y
L
T
Y
T
M
A
A
G
V
IP
T
A
V
1
0
23
A
S
in
gl
et
on
ne
w
S
T
1
(1
00
)
E
K
H
M
K
P
IA
Q
V
A
E
L
K
A
H
F
A
S
T
R
P
R
P
G
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
M
A
A
G
V
IP
T
A
V
1
0
12
F
98
9
98
9
1
(1
00
)
E
K
H
M
K
P
IA
Q
V
A
E
IK
A
H
F
A
S
T
R
P
G
R
S
S
Y
V
E
IE
0
1
N
S
Q
F
LA
G
S
F
S
Y
LT
Y
T
M
A
A
G
V
IP
T
A
V
1
0
A
ll
va
ria
nt
s
la
be
le
d
in
bo
ld
in
di
ca
te
st
ra
in
s
se
ns
iti
ve
to
bo
th
co
-t
rim
ox
az
ol
e
an
d
pe
ni
ci
lli
n,
M
LS
T
C
C
=
M
ul
til
oc
us
se
qu
en
ce
ty
pe
cl
on
al
co
m
pl
ex
,M
LS
T
S
T
=
M
LS
T
se
qu
en
ce
ty
pe
#
D
ih
yd
ro
fo
la
te
re
du
ct
as
e
(D
H
F
R
),
re
pr
es
en
ts
am
in
o
ac
id
re
si
du
es
14
–
14
9
in
th
e
am
in
o
ac
id
se
qu
en
ce
of
D
H
F
R
fr
om
S
.p
ne
um
on
ia
e
R
6,
th
e
am
in
o
ac
id
in
bo
ld
re
pr
es
en
tr
es
id
ue
s
92
an
d
10
0
*D
ih
yd
ro
pt
er
oa
te
sy
nt
ha
se
(D
H
F
S
),
R
ep
re
se
nt
s
am
in
o
ac
id
re
si
du
es
56
–
67
in
th
e
am
in
o
ac
id
se
qu
en
ce
of
D
H
P
S
fr
om
S
.p
ne
um
on
ia
e
R
6
§
T
hr
ee
va
ria
nt
s
ha
ve
no
tp
re
vi
ou
sl
y
be
en
re
po
rt
ed
¶
O
ne
st
ra
in
w
as
no
tf
ul
ly
ty
pe
d
fo
rp
en
ic
ill
in
re
si
st
an
ce
$
A
ll
se
ve
n
M
LS
T
al
le
le
s
un
av
ai
la
bl
e
fo
rt
he
se
st
ra
in
s
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
59
35
8.
t0
01
Invasive Pneumococcal Infections in Cambodian Children
PLOS ONE | DOI:10.1371/journal.pone.0159358 July 22, 2016 6 / 12
Discussion
In this study of 90 Cambodian children admitted to hospital with IPD, almost half of the chil-
dren were under two years of age and one in six died. The study isolates were collected during
the period before the start of PCV13 introduction. The range of pneumococcal serotypes deter-
mined in the available isolates was consistent with those in surrounding countries and with a
study conducted in 2013–14 at the same centre [2, 5–7, 15, 26–28]. PCV13 was introduced into
the national programme given as a 3+0 dosing schedule with no additional catch-up campaign,
with GAVI Alliance support, in January 2015 [29]. Our data suggests that the PCV13 will
potentially protect against the organisms causing 92% of IPD (95% CI 84%-99%) in these chil-
dren over this five-year period. In the study conducted in 2013–14, coverage by PCV13 was
88% for invasive strains and 63% in the colonizing strains (62–71%) [7].
The STs of serotype 1 (ST217), serotype 14 (ST63/784), and serotype 5 (ST289) strains were
similar to those found elsewhere. The serotype data was similar to the 2013–14 study with sero-
type 1 the most numerous, other serotypes were less common with the difference between the
Table 2. Antibiotic susceptibility of invasive S. pneumoniae isolates overall and by age of child.
Antimicrobial Number of isolates (%) susceptible
Under 2
years
n = 24
(%)
2–4
years
n = 13
(%)
5 years
and over
n = 13
(%)
All
patients
n = 50 (%)
Susceptible Intermediate Resistant
Penicillin
All strains—non-
meningitis
breakpoint1
24 (100) 13 (100) 13 (100) 50 (100)  2 4  8
All strains—
meningitis
breakpoint2
9 (38) 8 (62) 10 (77) 27 (54)  0.06 -  0.12
Non-meningitis
strains1
22/22
(100)
13/13
(100)
13/13
(100)
48/48
(100)
 2 4  8
Meningitis
strains2
1/2 (50) 0 0 1/2 (50)  0.06 -  0.12
Ceftriaxone
All strains—non-
meningitis
breakpoint1
23 (96) 13 (100) 13 (100) 49 (98)  1 2  4
All strains—
meningitis
breakpoint2
20 (83) 13 (100) 13 (100) 46 (92)  0.5 1  2
Non-meningitis
strains1
22/22
(100)
13/13
(100)
13/13
(100)
48/48
(100)
 1 2  4
Meningitis
strains2
2/2 (100) 0 0 2/2 (100)  0.5 1  2
Erythromycin3 15 (63) 8 (62) 12 (92) 35 (70)  21 16–20  152
Co-trimoxazole 6 (25) 2 (15) 3 (23) 11 (22)  0.5/9.5 1/19-2/38  4/76
Chloramphenicol3 21 (88) 8 (62) 6 (46) 35 (70)  21 - < 20
1 Susceptibility determined using the CLSI non-meningitis breakpoints with penicillin non-susceptibility
indicated by an MIC of >4μg/ml as per CLSI guidelines
2 Susceptibility determined using the CLSI meningitis breakpoints with penicillin non-susceptibility indicated
by an MIC of >0.06μg/ml as per CLSI guidelines
3 Antibiotic disc testing rather than MIC as per CLSI guidelines
doi:10.1371/journal.pone.0159358.t002
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studies difficult to evaluate [7, 30]. More than 10% of the other STs in this study were novel.
The number of multi-drug resistant (MDR, resistant to> 3 classes of drugs) invasive strains
was 46%, slightly lower than the level of 56% found in the subsequent study, although the sec-
ond study examined additional antibiotics [7]. The detection of serotypes 19A (ST320) and
23F (ST 9050) in Cambodia is interesting because of the potential for resistance gene transfer
to other strains in the same niche due to the high rate of recombination in S. pneumoniae.
Strains of the MDR resistant serotype 19A (ST320) have emerged in a number of Asian coun-
tries [31, 32]. Both 19A and 23F are covered by PCV13, therefore introduction of the vaccine
may lead to a decrease in antibiotic resistance in the S. pneumoniae strains circulating in
this region, although subsequently the NVTs described in Turner et al. were also resistant
[7, 31, 32].
Penicillin non-susceptibility using CLSI breakpoints according to the clinical syndrome,
was present in nearly half of the strains tested with two strains of intermediate susceptibility to
ceftriaxone using the CLSI meningitis breakpoints. All isolates were penicillin susceptible using
the recently revised CLSI pneumonia breakpoints. Two thirds of strains were resistant to co-tri-
moxazole consistent with the later local study [7]. The levels of resistance are broadly similar to
those in surrounding areas, which range in resistance levels from 33% (both intermediate and
fully resistant) in the Philippines to 99% in India [33]. The proportion of strains resistant to
erythromycin was the same as invasive isolates in the later local study [7], similar to one study
in the region [34], but lower than others [35, 36]. Resistance is likely to be driven by the overuse
of antibiotics in the community. Antibiotics can be obtained without prescription or the need
for a medical consultation in Cambodia and may be given at sub-therapeutic doses and for a
shorter period than recommended. Our recent study documented that one third of patients
attending AHC out-patients had evidence of recent antibiotic use, and in addition use of sub-
standard antibiotics is likely to be widespread [37, 38]. Drug quality in developing countries is
difficult to measure and drug regulations can be difficult to enforce, leading to a large market
in low-quality antimicrobials, in turn contributing to an increase in antimicrobial resistance of
bacteria in the region.
With increasing use of WGS of clinical isolates a greater variety of resistance genotypes for
different antibiotics are likely to be identified [22]. The penicillin genotypes in this study have
been described in more detail elsewhere and no single pattern was associated with non-suscep-
tibility [23]. A large number of the strains showed phenotypic resistance to co-trimoxazole and
WGS identified eight different genotypes for the DHFS and seventeen for the DHFR [39].
Table 3. Minimum inhibitory concentrations (MICs) for penicillin and ceftriaxone by disease.
Disease Total number Samples examined for MIC Penicillin MIC Penicillin
category1
n (%)
Ceftriaxone MIC Ceftriaxone
category1 n(%)
MIC50 MIC90 Range S I R MIC50 MIC90 Range S I R
Pneumonia 47 (52.2) 28 (56.0) 0.016 0.50 0.006–1.00 28 0 0 0.047 0.38 0.004–0.75 28 0 0
Bacteremia 16 (17.8) 10 (20.0) 0.008 0.94 0.002–1.50 10 0 0 0.064 0.75 0.003–1.00 10 0 0
Septic shock 12 (13.3) 5 (10.0) 0.016 0.38 0.012–0.38 5 0 0 0.016 0.38 0.012–0.38 5 0 0
Meningitis 8 (8.9) 2 (4.0) 0.008 0.051 0.008–0.094 1 0 1 0.030 0.047 0.012–0.047 2 0 0
Cellulitis 2 (2.2) 1 (2.0) 0.016 - - 1 - - 0.012 - - 1 - -
Pyomyositis 1 (1.1) 0 - - - - - - - - - - - -
Uncertain site 4 (4.4) 4 (8.0) 0.056 0.75 0.012–0.75 4 0 0 0.072 0.50 0.012–0.50 4 0 0
Total 90 50 0.06 0.5 0.03–2.0 49 0 1 0.05 0.5 0.03–1.00 50 0 0
1 Penicillin parenteral and ceftriaxone categorization using non-meningitis or meningitis breakpoints according to the site of infection as per CLSI guidelines,.
S: susceptible, I: intermediate; R: resistant
doi:10.1371/journal.pone.0159358.t003
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A single genotype accounted for the majority of the susceptible Cambodian strains (DHFS:
STRPGSSYVEIE and DHPS: EEHMKPIAQVAEIKAHFA), this genotype was not restricted to
serotype/ST (present in serotypes 5, 9V, 24F, 18C, 3 and 38). All of the resistant strains con-
tained the amino acid leucine at position 100 substituted in place of isoleucine in DHFS [40].
Thirty one (62%) of the co-trimoxazole resistant strains contained the 6bp insertion in DHPS
and eight contained a 3bp insertion that has also been described in Malawi [23]. Three novel
co-trimoxazole resistance genotypes are described in the current work including one genotype
(two strains) that contained a 3bp insertion and another that contained a novel 6bp insertion.
Although co-trimoxazole resistance is high in Cambodia, current use of the drug is mainly for
treating patients with melioidosis or in those infected with HIV.
This study has a number of limitations including the retrospective design and relatively the
small numbers of IPD cases. Reassuringly the results are broadly consistent with a subsequent
prospective study at the same site [7]. Only a sub-set of the isolates was available for further
testing because a number of strains could not be re-grown when sub-cultured. This limited the
analysis of serotype distribution and antibiotic resistance patterns. The gradual improvement
of laboratory capacity which has increased the isolation rates in the present study, together
with the improved awareness of the utility of microbiology by local clinicians since 2005 con-
tributed to the improved blood culture yield observed in the 2013–14 study. Antibiotic pre-
treatment in the community before hospital admission is common and may have biased the
isolates toward more resistant strains. Data from this single site may not be generalizable to the
whole of Cambodia and data from other sites are needed.
Conclusions
This study covering the period 2007 to 2012 confirms and extends the 2013–14 data from the
same centre, the use of whole genome sequencing in the present study provided additional typ-
ing and resistance information with the description of novel sequence types and resistotypes. It
highlights a high mortality associated with invasive pneumococcal disease in hospitalized Cam-
bodian children and the potential benefit of the PCV13 vaccination program. It emphasizes the
need for detailed prospective studies to describe the serotypes of carriage and invasive pneumo-
cocci circulating in Cambodia after vaccine introduction.
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